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Ba
fHoBACKGROUND Pre-reperfusion administration of intravenous (IV) metoprolol reduces infarct size in ST-segment
elevation myocardial infarction (STEMI).
OBJECTIVES This study sought to determine how this cardioprotective effect is inﬂuenced by the timing of metoprolol
therapy having either a long or short metoprolol bolus-to-reperfusion interval.
METHODS We performed a post hoc analysis of the METOCARD-CNIC (effect of METOprolol of CARDioproteCtioN
during an acute myocardial InfarCtion) trial, which randomized anterior STEMI patients to IV metoprolol or control before
mechanical reperfusion. Treated patients were divided into short- and long-interval groups, split by the median time from
15 mg metoprolol bolus to reperfusion. We also performed a controlled validation study in 51 pigs subjected to 45 min
ischemia/reperfusion. Pigs were allocated to IV metoprolol with a long (25 min) or short (5 min) pre-perfusion
interval, IV metoprolol post-reperfusion (þ60 min), or IV vehicle. Cardiac magnetic resonance (CMR) was performed
in the acute and chronic phases in both clinical and experimental settings.
RESULTS For 218 patients (105 receiving IV metoprolol), the median time from 15 mg metoprolol bolus to reperfusion
was 53 min. Compared with patients in the short-interval group, those with longer metoprolol exposure had smaller
infarcts (22.9 g vs. 28.1 g; p ¼ 0.06) and higher left ventricular ejection fraction (LVEF) (48.3% vs. 43.9%; p ¼ 0.019) on
day 5 CMR. These differences occurred despite total ischemic time being signiﬁcantly longer in the long-interval group
(214 min vs. 160 min; p < 0.001). There was no between-group difference in the time from symptom onset to metoprolol
bolus. In the animal study, the long-interval group (IV metoprolol 25 min before reperfusion) had the smallest infarcts
(day 7 CMR) and highest long-term LVEF (day 45 CMR).
CONCLUSIONS In anterior STEMI patients undergoing primary angioplasty, the sooner IV metoprolol is adminis-
tered in the course of infarction, the smaller the infarct and the higher the LVEF. These hypothesis-generating
clinical data are supported by a dedicated experimental large animal study. (J Am Coll Cardiol 2016;67:2093–104)
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ABBR EV I A T I ON S
AND ACRONYMS
CMR = cardiac magnetic
resonance
HF = heart failure
LV = left ventricular
LVEF = left ventricular ejection
fraction
MI = myocardial infarction
MIS = myocardial infarct size
PPCI = primary percutaneous
coronary intervention
STEMI = ST-segment elevation
myocardial infarction
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2094T imely reperfusion is the mainstaytreatment for patients presentingwith ST-segment elevation myocar-
dial infarction (STEMI). The preferred reper-
fusion strategy is primary percutaneous
coronary intervention (PPCI), ideally within
120 min of STEMI diagnosis (1,2). Adjunct
treatments for patients undergoing PPCI are
mainly aimed at preventing thrombotic com-
plications, not reducing myocardial loss per
se. Myocardial infarct size (MIS) is a major
determinant of post-STEMI mortality and
morbidity (3). Patients with a large MIS and
associated left ventricular (LV) systolic
dysfunction are at high risk of long-termheart failure (HF) readmission and sudden death (4).
Indeed, post-STEMI severe LV dysfunction is a
Class I indication for insertion of an implantable
cardioverter-deﬁbrillator (ICD) (5).SEE PAGE 2105Administration of 15mg intravenous (IV)metoprolol
before reperfusion in STEMI patients undergoing PPCI
was recently shown to reduce cardiac magnetic reso-
nance (CMR)–measured infarct size in theMETOCARD-
CNIC (effect of METOprolol of CARDioproteCtioN
during an acute myocardial InfarCtion) trial (6).
Besides reducing acute infarct size, pre-reperfusion
15 mg metoprolol administration was associated with
improved long-term LV systolic function, fewer in-
dications for ICD insertion, and fewer HF readmissions
(7). In the METOCARD-CNIC trial, patients were
recruited and randomized to 15 mg IV metoprolol or
control before arterial access, either during ambulance
transit or at the PPCI hospital. Patients allocated to
IV metoprolol therefore received the drug at varying
intervals before reperfusion. No previous evaluation
has considered the cardioprotective effect of theversidad Francisco de Vitoria, Madrid, Spain; iPhilips Healthcare I
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received January 27, 2016; revised manuscript received Februartiming of pre-reperfusion metoprolol administration
(long or short pre-reperfusion interval). Identifying
the best timing and setting for metoprolol adminis-
tration for attaining cardioprotection (the out-of-
hospital setting or the more controlled hospital/
catheterization laboratory environment) has implica-
tions for the chain of care for STEMI patients.
Here we present a post hoc analysis of the
METOCARD-CNIC trial and a subsequent large animal
ischemia/reperfusion experimental study designed to
validate the hypothesis generated with the clinical
trial data. In both cases, the effect of the timing of
metoprolol administration on cardioprotection (MIS
and left ventricular ejection fraction [LVEF]) was
evaluated by state-of-the-art CMR.
METHODS
A translational project was designed to evaluate how
the timing of pre-reperfusion IV metoprolol admin-
istration affects cardioprotection in STEMI patients.
First, a hypothesis was generated from an exploratory
clinical study (post hoc analysis of METOCARD-CNIC
clinical trial). Then, a controlled experimental study
in a large animal model of acute myocardial infarction
(MI) was designed to conﬁrm the hypothesis gener-
ated in the clinical study.
Patients with anterior STEMI undergoing PPCI were
recruited within the METOCARD-CNIC trial (6).
Patients underwent 2 CMR studies 5 to 7 days and 6
months after STEMI. Inclusion/exclusion criteria and
the study protocol have been published previously (8).
Brieﬂy, METOCARD-CNIC is a randomized clinical trial
that recruited patients with ﬁrst anterior STEMI who
presented early (<6 h from symptom onset) and were
undergoing PPCI. Patients were randomized to receive
15 mg IV metoprolol or control before reperfusion.
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20955 to 7 days post-infarction (6); secondary endpoints
included LV performance assessed by CMR at 6months
post-infarction (7). A total of 270 patients were
recruited to the METOCARD-CNIC trial, 220 of whom
underwent CMR for MIS quantiﬁcation. Patients with
complete 5- to 7-day CMR and time period data
(n ¼ 218) were included in this analysis. To study the
effect of metoprolol timing on cardioprotection, we
divided patients allocated to IV metoprolol into
2 groups according to whether the metoprolol-to-
reperfusion interval was longer (long-interval group)
or shorter (short-interval group) than the median
value.
The CMR protocol and methods for imaging anal-
ysis are described in detail elsewhere (8).
ANIMAL STUDY DESIGN. Experiments were per-
formed in castrated male Large-White pigs, and MI
was induced experimentally by closed-chest, 45-min
left anterior descending (LAD) coronary artery
occlusion followed by chronic reperfusion. Animals
were allocated 1:1:1:1 in a blinded fashion by adaptive
randomization to the following treatments: 1) vehicle
(control-vehicle group); 2) IV metoprolol (0.75 mg/kg)
25 min before reperfusion (long-interval group);
3) the same metoprolol bolus given 5 min
before reperfusion (short-interval group); and 4) IV
metoprolol held until 60 min after reperfusion
(post-reperfusion group). Metoprolol and vehicle
were prepared in numbered syringes before MI
induction and administered by blinded operators at
each time point according to the animal’s allocation.
To ensure blinded intervention and analysis, all ani-
mals received 3 injections: 1 at each treatment time
point, with metoprolol reserved for a single injection
on the basis of randomized group. To mimic the
clinical scenario, all animals (including those allo-
cated to control-vehicle) received 50 mg of oral
metoprolol daily throughout the duration of the
study, starting 1 day after reperfusion. The study
protocol was approved by the Institutional Animal
Research Committee and conducted in accordance
with recommendations of the Guide for the Care and
Use of Laboratory Animals.
MI PROCEDURE AND INVASIVE HEMODYNAMIC
ASSESSMENT. The protocol for MI induction has
been detailed elsewhere (9–11). Brieﬂy, the LAD coro-
nary artery immediately distal to the origin of the ﬁrst
diagonal branch was occluded for 45 min with an
angioplasty balloon introduced via the percutaneous
femoral approach. Balloon location and state of inﬂa-
tion were monitored regularly by angiography. After
balloon deﬂation, a coronary angiogram was recorded
to conﬁrm patency of the coronary artery. In cases ofventricular ﬁbrillation (VF), a biphasic deﬁbrillator
was used to deliver nonsynchronized shocks as
needed. Post-operative animal recovery and care were
carried out by CNIC veterinarians and technicians.
Hemodynamic measures were assessed at 3 time
points during the MI procedure: at baseline, after
40 min of ongoing ischemia (5 min before reperfu-
sion), and at 45 min post-reperfusion. Right heart
catheterization was performed with a Swan-Ganz
catheter introduced percutaneously through the
femoral vein under ﬂuoroscopy in the catheterization
laboratory. Hemodynamic measurements included
systolic, mean, and diastolic systemic artery pressure;
systolic, mean, and diastolic pulmonary artery pres-
sure; pulmonary capillary wedge pressure; and right
ventricle cardiac output assessed by the thermodilu-
tion method.
ANIMAL CMR PROTOCOL. CMR studies were per-
formed 7 and 45 days after acute MI to assess MIS and
LV performance. Pigs were anesthetized, and anes-
thesia was maintained by continuous intravenous
infusion of midazolam. CMR studies were performed
using a 3-T Achieva Tx whole body scanner (Philips
Medical Systems, Best, the Netherlands) equipped
with a 32-element cardiac phased-array surface coil.
Images were acquired with the use of electrocardio-
gram gating by operators blinded to the study arm.
Segmented cine steady-state free precession was
performed to acquire 11 to 13 contiguous short-axis
slices covering the heart from the base to the apex
to evaluate global and regional LV motion. CMR
parameters can be found in the Online Appendix.
All CMR images were analyzed using dedicated
software (QMass MR version 7.6, Medis, Leiden, the
Netherlands). Images were analyzed by 2 experienced
observers (J.M.G.-R. and C.G.-A.) with vast experi-
ence in CMR analysis and blinded to study allocation.
The analysis protocol has been detailed elsewhere (9).
Brieﬂy, LV cardiac borders were traced in each short-
axis cine image to obtain LV end-diastolic volume, LV
end-systolic volume, and LVEF. LV volumes and mass
were normalized to body surface area according to
Brody’s formula (12). CMR post-processing is
described in the Online Appendix.
STATISTICAL ANALYSIS. The distribution of contin-
uous variables was analyzed with graphical methods.
For normally distributed variables, results are
expressed as mean  SD; otherwise they are repre-
sented as median (interquartile range [IQR]). Cate-
gorical variables are expressed as absolute frequency
(%). Comparisons among groups were performed
by parametric methods (nonpaired Student t test
and 1-way analysis of variance, applying Welch’s
FIGURE 1 Time Interval Periods by Group
Long-interval
group
Short-interval
group
Control
Total ischemic time: 214 [78] min
Total ischemic time: 160 [71] min
Total ischemic time: 180 [82] min
Reperfusion
135 [88] min 79 [27] min
130 [72] min 35 [17] min
110 [94] min 70 [48] min
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Long and short intervals refer to the time from metoprolol administration to reperfusion, split by the median value. Values are median
[interquartile range]. i.v. ¼ intravenous.
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2096correction when needed) or nonparametric methods
(Kruskal-Wallis, Mann-Whitney U, and Fisher exact
test) as appropriate. In the clinical study, time from IV
metoprolol to reperfusion was converted to a cate-
gorical variable by using a median split to generate
2 groups: those with a metoprolol-to-reperfusion in-
terval shorter than the median (short-interval group)
and longer than the median (long-interval group);
multivariate linear regression methods, adjusting for
total ischemic time, were used for comparisons among
groups (control, short-interval, and long-interval).
To check consistency of results, 2 sensitivity ana-
lyses were performed. First, linear regression was
used to assess the association of metoprolol-to-
reperfusion time (as a continuous variable) with MIS
and other LV performance parameters. Second,
because metoprolol-to-reperfusion time was available
only for patients who received IV metoprolol, a
multivariate linear regression analysis was performed
to assess the interaction between treatment group and
time from randomization to reperfusion, which was
available for the whole cohort, including control sub-
jects (Figure 1 for time-period deﬁnitions). Sequential
Holm-Bonferroni correction for pre-speciﬁed multiple
comparisonswas applied. Differenceswere considered
statistically signiﬁcant at p value <0.05 (2-tailed).
Additional information about the methods used is
found in the Online Appendix.RESULTS
CLINICAL STUDY. The clinical study population con-
sisted of the 220 patients in the METOCARD-CNIC
clinical trial in whom MIS was assessed by CMR at
day 5 to 7 post-STEMI. Time period data were
incomplete for 2 patients, who thus were excluded
from this analysis. Therefore, the ﬁnal cohort in the
clinical study included 218 patients. In the overall
cohort, the median time from symptom onset to
reperfusion was 185 min (IQR: 144 to 225 min),
whereas median time from randomization to reper-
fusion was 70 min (IQR: 45 to 94 min). A diagram
showing all relevant time intervals is presented in
Figure 1. For the analysis, the intervention group was
split according to the median time from IV metoprolol
to reperfusion (53 min), thus deﬁning long- and
short-interval groups. Final group sizes were 52, 53,
and 113 patients for the long-interval, short-interval,
and control groups, respectively. Total ischemic time
was 214 min (IQR: 169 to 248 min) in the long-interval
group and 160 min (IQR: 135 to 206 min) in the
short-interval group. Baseline characteristics of the
clinical study population are presented in Table 1.
TIME-BASED EFFECT OF IV METOPROLOL ON MIS.
Infarct size was calculated as percentage of left ven-
tricular mass (%LV). Mean values in the long-interval,
short-interval, and control groups were 19.3  10.7%,
TABLE 1 Baseline Characteristics of the Clinical Study Cohort
Long Interval
(n ¼ 52)
Short Interval
(n ¼ 53)
Control
(n ¼ 113) p Value
Age, yrs 58.1  12.8 59.0  12.5 58.6  10.4 0.915
Male 44 (84.6) 47 (88.7) 99 (87.6) 0.832
Body mass index, kg/m2 27.7  3.2 27.3  3.8 27.8  3.9 0.741
Hypertension 19 (37.3) 20 (37.7) 47 (41.6) 0.869
Smoking 0.964
Current 27 (52.9) 27 (50.9) 60 (53.1) —
Former (0–10 yrs prior) 6 (11.8) 7 (13.2) 11 (9.7) —
Dyslipidemia 26 (51.0) 18 (34.0) 46 (40.7) 0.205
Diabetes 11 (21.6) 11 (20.8) 21 (18.6) 0.877
Total ischemic time, min 214 (169–248) 160 (135–206) 180 (143–225) 0.001
Time from symptom onset to
metoprolol bolus, min
135 (77–165) 130 (105–176) — 0.430
Time from randomization to
PCI, min
95 (84–116) 45 (30–55) 70 (42–90) <0.001
TIMI ﬂow grade 0–1 before PCI 39 (75.0) 45 (84.9) 92 (81.4) 0.425
TIMI ﬂow grade 3 after PCI 33 (63.5) 41 (77.4) 84 (73.4) 0.236
Killip-Kimball I 48 (92.3) 48 (90.6) 100 (88.5) 0.976
Systolic blood pressure at
recruitment, mm Hg
144  20 141  16 142  19 0.795
Diastolic blood pressure at
recruitment, mm Hg
93  15 86  17 87  15 0.035
Heart rate at recruitment,
beats/min
80  12 84  15 82  14 0.478
Systolic blood pressure after IV
metoprolol, mm Hg
131  19 125  16 — 0.124
Diastolic blood pressure after IV
metoprolol, mm Hg
85  17 80  13 — 0.063
Heart rate after IV metoprolol,
beats/min
68  8 69  15 — 0.497
Values are mean  SD, n (%), or median (interquartile range). Bold indicates statistical signiﬁcance.
IV ¼ intravenous; PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
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209722.9  12.2%, and 25.2  13.8%, respectively
(p ¼ 0.009); the adjusted treatment effect of
long-interval versus control was 5.6% (95% conﬁ-
dence interval [CI]: 10.1% to 1.1%; p ¼ 0.016) and
that of long-interval versus short-interval was 4.5%
(95% CI: 9.4% to 0.5%; p ¼ 0.076) (Figures 2A and 2B).
Consistently, mean LVEF assessed at day 5 CMR in the
long-interval, short-interval, and control groups was
48.3  8.5%, 43.9  9.8%, and 43.4  10.3%, respec-
tively; the adjusted treatment effect of long-interval
versus control was 5.1% (95% CI: 1.7% to 8.4%;
p¼0.003) and that of long-interval versus short-interval
was 4.5% (95%CI: 0.8% to8.3%; p¼0.019) (Figure 2C). At
6-month CMR, the beneﬁcial effect of early IV
metoprolol administration on LVEF was maintained,
with an adjusted treatment effect of long-interval
versus control of 4.6% (95% CI: 0.6% to 8.6%;
p ¼ 0.023), and an adjusted treatment effect of
long-interval versus short-interval of 3% (95% CI:1.3%
to 7.2%; p ¼ 0.172). Complete CMR data are presented
in Table 2.
The consistency of the results was checked with 2
sensitivity analyses. First, analysis of patients allo-
cated to IV metoprolol showed that the sooner the
drug was administered, the smaller the MIS and
higher the LVEF: every 10 min of “on-board” meto-
prolol was associated with an MIS reduction of 1.1 g
(95% CI: 2.1 to 0.0 g; p ¼ 0.049) and an increase in
LVEF of 0.6% (95% CI: 0.1% to 1.2%; p ¼ 0.092) at
5 days post-reperfusion (Table 3, Figure 3A). Second,
the analysis was replicated in the complete cohort,
using randomization-to-reperfusion time instead of
IV metoprolol-to-reperfusion time (see the Methods
section); this analysis showed an effect modiﬁcation
(interaction) between IV metoprolol treatment and
randomization-to-reperfusion time (Figure 3B).
ANIMAL STUDY. Experimental MI was induced in
51 Large-White pigs (31  2.4 kg) by percutaneous
angioplasty (45 min of balloon-mediated, LAD
coronary occlusion) followed by reperfusion. Nine
animals died before completing the 7-day CMR
(3 allocated to the control-vehicle group, 2 to
long-interval metoprolol, 1 to short-interval meto-
prolol, and 3 to post-reperfusion metoprolol). Thus,
the ﬁnal group sizes were 11, 12, 10, and 9 animals for
the long-interval, short-interval, post-reperfusion,
and vehicle groups, respectively. Six additional ani-
mals died suddenly before completing the 45-day
CMR. Table 4 contains ﬁnal numbers of animals
per group.
There were no among-group differences in hemo-
dynamic status at baseline, and the timing of IV
metoprolol administration was not associated with
stable hemodynamic differences among treatmentgroups. Complete hemodynamic data are presented in
Online Table 1.
CARDIOPROTECTION OF IV METOPROLOL AND
TIMING OF ADMINISTRATION. On day 7 CMR, infarcts
were signiﬁcantly smaller in the long-interval group:
median 23.3% (IQR: 20.1% to 24.2%) (%LV) versus
26.7% (IQR: 23.1% to 32.1%) in the short-interval group
(p ¼ 0.028) and 27.3% (IQR: 23.4% to 31.1%) in the
control-vehicle group (p ¼ 0.049) (Figure 4A). Consis-
tent with these data, the long-interval group showed
more favorable LV remodeling at day-45 CMR: pigs
receiving IV metoprolol early during the ongoing
ischemia had smaller LV volumes and higher LVEF
than those in the control-vehicle group (LVEF: median
38.9% [IQR: 32.6% to 45.3%] vs. 29.1% [IQR: 25.8% to
35.4%]; p ¼ 0.042) (Figure 4C). Conversely, adminis-
tration of IV metoprolol just before reperfusion had no
signiﬁcant cardioprotective effect: MIS on day-7 CMR
did not differ between the short-interval and
control-vehicle groups (26.7% [IQR: 23.1% to 32.1%] vs.
27.3% [IQR: 23.4% to 31.1%]; p ¼ 1.0) (Figure 4A). Full
CMR-derived data are presented in Table 4.
FIGURE 2 MIS and LVEF Assessed by CMR
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At 5 days post-infarction, cardiac magnetic resonance imaging
(CMR) showed myocardial infarct size (IS) expressed as (A) a
percentage of left ventricle mass (%LV) and (B) as a percentage
of the area at risk (AAR); (C) shows left ventricular ejection
fraction (LVEF). Dots indicate individual data, bars indicate mean
(standard error of the mean). MIS ¼ myocardial infarct size.
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In this study, we evaluated the effect of different pre-
reperfusion timings of IV metoprolol on car-
dioprotection (infarct size and LVEF) in a post hoc
analysis of the METOCARD-CNIC trial and in a trans-
lational model of ischemia/reperfusion. In the clinical
trial, we found that the longer the time between
15-mg IV metoprolol administration and reperfusion,
the greater the MIS reduction and the better the LV
function at 6-month follow-up (Central Illustration).
After reviewing these hypothesis-generating data, we
conducted a large animal (pig) study speciﬁcally
designed to conﬁrm the hypothesis. Pigs undergoing
experimental myocardial ischemia/reperfusion were
randomized to receive vehicle or IV metoprolol with a
long or short interval before reperfusion, or after
reperfusion. Animals receiving IV metoprolol long
before reperfusion had signiﬁcantly smaller infarcts
at short term and a better long-term LV performance
than the other groups, consistent with the results of
the clinical study. Our results suggested that, in pa-
tients with no contraindications, the sooner meto-
prolol is injected in the course of STEMI, the greater
the protection against myocardial death.
We previously demonstrated, using the same ani-
mal model, that metoprolol reduces infarct size
(13), but only when administered before reperfusion
(14). These studies, which set the basis for the
METOCARD-CNIC trial, left unanswered the question
of whether the infarct-limiting effects of metoprolol
are affected by the timing of pre-reperfusion admin-
istration, a question tackled in the present combined
clinical-experimental study. To answer the main
question posed in this study, we converted the time
from IV metoprolol to reperfusion into a categorical
variable by splitting treated patients into 2 groups
according to the median time between metoprolol
bolus and reperfusion (53 min). Patients in the long-
interval group had smaller infarcts than those
receiving metoprolol closer to the time of reperfu-
sion. To exclude the possibility that this artiﬁcial
division might have biased the results, we also per-
formed a continuous analysis, which documented
a negative correlation between metoprolol-to-
reperfusion interval and MIS (Figure 3A). The animal
study results agreed with both clinical analyses:
pigs receiving metoprolol long before reperfusion
(at midischemia) had signiﬁcantly smaller infarcts
and higher long-term LVEF than animals receiving
metoprolol just before or after reperfusion and
control subjects. The similar ﬁndings from 3
separate analyses provide strong support for the
conclusions reached.
TABLE 2 Clinical Study: CMR-Derived Parameters
Long Interval
ANOVA Linear Trend vs. Control* vs. Short Interval*
Long Interval Short Interval Control p Value p Value Difference (95% CI) p Value Difference (95% CI) p Value
5-day CMR
n 52 53 113
LVEDVi, ml/1.73 m2 149.6  33.7 153.4  23.3 154.8  31.5 0.601 — 4.6 (15.6 to 6.5) — 4.9 (6.8 to 7) —
LVESVi, ml/1.73 m2 78.7  26.4 86.9  23.5 89.3  29.7 0.079 0.031 10.4 (20.3 to 0.5) 0.039 9.3 (19.7 to 1) 0.077
LV mass, g 106.8  23 111  26.5 112.9  26.1 0.366 — 6.6 (15.2 to 2.0) — 3.7 (14.0 to 6.5) —
AAR, %LV 29.1  11.5 30.7  11.9 31.3  12.8 0.601 — 2.0 (6.2 to 2.3) — 1.1 (602 to 3.8) —
Infarct size, g 22.9  14 28.1  16.3 32.4  22.2 0.014 0.003 9.7 (16.6 to 2.9) 0.006 6.0 (12.3 to 0.3) 0.06
Infarct size, %LV 19.3  10.7 22.9  12.2 25.2  13.8 0.03 0.009 5.6 (10.1 to 1.1) 0.016 4.5 (9.4 to 0.5) 0.076
Infarct size, %AAR 61.8  24.1 69.3  20.5 73.2  22.9 0.016 0.005 11.5 (19.7 to 3.3) 0.006 10.6 (19.9 to 1.3) 0.026
LVEF, % 48.3  8.5 43.9  9.8 43.4  10.3 0.011 0.006 5.1 (1.7 to 8.4) 0.003 4.5 (0.8 to 8.3) 0.019
6-month CMR
n 46 51 100
LVEDVi, ml/1.73 m2 165.4 (34.8) 169.8 (32.6) 176 (38) 0.227 — 9.9 (23.1 to 3.4) — 7.7 (21.9 to 6.6) —
LVESVi, ml/1.73 m2 84.9  30.9 91.7  35.1 99.7  39.1 0.064 0.019 13.8 (26.9 to 0.7) 0.040 10 (24.1 to 4.1) 0.162
Infarct size, g 14.5  11.4 17.1  9.7 18.6  11.4 0.121 — 3.9 (8.1 to 0.3) — 3.5 (8.1 to 1.1) —
Infarct size, %LV 13.9  9.6 17.5  9.5 18.3  9.9 0.045 0.019 4.2 (7.8 to 0.6) 0.023 4.4 (8.5 to 0.2) 0.038
Infarct size, %AAR† 45.2  25 53.1  19.3 55.5  20.8 0.032 0.012 10.6 (18.8 to 2.4) 0.011 11.6 (21 to 2.2) 0.015
LVEF, % 49.9  11.1 47.4  10.5 45  11.8 0.038 0.011 4.6 (0.6 to 8.6) 0.023 3.0 (1.3 to 7.2) 0.172
Values are mean  SD unless otherwise indicated. Bold indicates statistical signiﬁcance. *Adjusted by total ischemic time. †Infarct size normalized by myocardium at risk at 5-day CMR.
AAR ¼ area at risk; ANOVA ¼ analysis of variance; CI ¼ conﬁdence interval; CMR ¼ cardiac magnetic resonance imaging; LV ¼ left ventricle; LVEDVi ¼ left ventricular end-diastolic volume index;
LVEF ¼ left ventricular ejection fraction; LVESVi ¼ left ventricular end-systolic volume index.
TABLE 3 Sensitivity Analysis of CMR-Derived Parameters in
Patients Receiving IV Metoprolol
Effect on LV Performance
Per 10 min “Onboard” Metoprolol
Duration*
Adjusted Mean Difference
(95% CI) p Value
5-day CMR
LVEDVi, ml/1.73 m2 1.5 (3.5 to 0.5) 0.144
LVESVi, ml/1.73 m2 1.5 (3.3 to 0.2) 0.088
LV mass, g 1.1 (2.8 to 0.7) 0.225
AAR, %LV 0.2 (1.1 to 0.6) 0.584
Infarct size, g 1.1 (2.1 to 0.0) 0.049
Infarct size, %LV 0.8 (1.6 to 0.1) 0.071
Infarct size, %AAR 1.9 (3.5 to 0.3) 0.022
LVEF, % 0.6 (0.1 to 1.2) 0.092
6-month CMR
LVEDVi, ml/1.73 m2 1.3 (3.9 to 1.2) 0.297
LVESVi, ml/1.73 m2 1.6 (4.1 to 0.9) 0.214
Infarct size, g 0.7 (1.5 to 0.1) 0.071
Infarct size, %LV 0.8 (1.5 to 0.1) 0.032
Infarct size, %AAR† 2.2 (3.8 to 0.5) 0.012
LVEF, % 0.5 (0.2 to 1.3) 0.162
Bold indicates statistical signiﬁcance. *In the IV metoprolol group (adjusted for
total ischemic time). †Infarct size normalized by myocardium at risk at 5-day CMR.
Abbreviations as in Tables 1 and 2.
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2099Administration of IV b-blockers is recommended
by the American College of Cardiology/American
Heart Association guidelines (Class IIa, Level of Evi-
dence: B) as well as the European Society of Cardiol-
ogy guidelines (Class IIa, Level of Evidence: B) for
STEMI patients who are without contraindications
and are hypertensive (1,2) or show “signs of ongoing
ischemia” (1). Both clinical guidelines specify
administration of IV b-blockers at the time of pre-
sentation; however, there have been no data to sup-
port this recommended timing in patients reperfused
by PPCI. The data presented here conﬁrm the value of
early IV administration of b-blockers recommended
by the clinical guidelines. Obviously, this early
administration is only of value if the IV route is
used. However, despite IV b-blocker administration
being a Class IIa recommendation, penetrance in
real-world data is extremely low (15–17), most likely
due to the potential side effects of IV b-blockers
when administered early in the course of STEMI
(18). In the METOCARD-CNIC clinical trial, exclusion
criteria included signs of HF, systolic blood
pressure <120 mm Hg, or any degree of atrioventric-
ular block (8). Patients in the IV metoprolol and
control arms showed no differences in the incidence
of side effects, including cardiogenic shock (6).
FIGURE 3 Association Between Metoprolol Bolus-to-Reperfusion Time Interval and Infarct Size
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Per sensitivity analyses, (A) myocardial infarct size (MIS) decreases in a linear fashion the longer the time from intravenous (IV) metoprolol bolus to
percutaneous coronary intervention (PCI) within the subset of patients receiving IV metoprolol. Blue dots indicate individual data in the metoprolol-treated
group; blue line indicates linear relationship between MIS and the time interval from IV metoprolol bolus to PCI; dashed orange line indicates mean MIS
value for the control group. (B) An effect modiﬁcation was also seen between IV metoprolol treatment and time from randomization to PCI in the complete
clinical-study cohort. Blue dots indicate individual data in the metoprolol-treated group; orange dots indicate individual data in the complete cohort; lines
indicate linear relation between MIS and time from randomization to PCI. i.v. ¼ intravenous.
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2100Absence of increased metoprolol-related side effects
was also apparent in a separate analysis of the sub-
group of patients recruited in the out-of-hospital
setting (19).TABLE 4 Animal Study: CMR-Derived Parameters
60 Min
Long Interval Short Interval Post-R
7-day CMR
n 11 12
LVEDV, ml/m2 131.4 (120.1–137.9) 132.4 (117.8–139.5) 139.5 (1
LVESV, ml/m2 79.5 (69.1–91.4) 83.1 (73.5–93.7) 91.3 (7
LVEF, % 38.6 (35.1–43.5) 36.9 (32.8–41.6) 31.3 (2
AAR, %LV 30.3 (28.8–31.8) 25.7 (23.9–32.8) 31.9 (2
Infarct size, %LV 23.3 (20.1–24.2) 26.7 (23.1–32.1) 28.6 (2
Infarct size, %AAR 76.6 (70.8–86.7) 96.5 (87.1–100) 90.7 (8
45-day CMR
n 11 9
LVEDV, ml/m2 127 (121.8–132.8) 144.2 (127.8–149.3) 144.1 (1
LVESV, ml/m2 77.6 (67.9–84.7) 91.8 (82.5–98) 90.2 (8
LVEF, % 38.9 (32.6–45.3) 36.5 (33.2–37.2) 33 (2
Infarct size, %LV 16.6 (15–21.7) 21.2 (19.3–23.3) 22 (1
Infarct size, %AAR* 57.2 (50.5–73.7) 73.0 (58.1–79.9) 74.6 (5
Values are median (interquartile range) unless otherwise indicated. Bold indicates statis
LVEDV ¼ left ventricular end-diastolic volume; LVESV ¼ left ventricular end-systolicThe METOCARD-CNIC clinical trial was the ﬁrst
to compare 2 different strategies of b-blocker admin-
istration/initiation in STEMI patients undergoing
PPCI: IV metoprolol before reperfusion versusLong Interval
eperfusion Vehicle p Value
p Value vs.
Vehicle
p Value vs.
Short Interval
10 9
08.9–161.3) 132.1 (121–140.3) 0.909 — —
4.1–112.4) 81.4 (77.4–94.9) 0.476 — —
9.3–38.2) 36.3 (33.3–39.7) 0.102 — —
5–42.8) 29.9 (27.1–33) 0.63 — —
4–37) 27.3 (23.4–31.1) 0.034 0.028 0.049
7.3–95.6) 93.1 (83.8–97.9) 0.005 0.007 0.004
8 8
27.8–171.4) 148.7 (138–189.1) 0.030 0.012 0.074
5.1–118.2) 105.8 (90.8–142.7) 0.013 0.012 0.063
9.6–38.8) 29.1 (25.8–35.4) 0.058 0.042 0.342
9.1–32.5) 20.9 (17.1–30.1) 0.115 — —
5.8–83.4) 75.9 (65.8–95.2) 0.148 — —
tical signiﬁcance. *Infarct size normalized by myocardium at risk at 7-day CMR.
volume; other abbreviations as in Table 2.
FIGURE 4 Pig Model of Ischemia/Reperfusion
*
*
*
50
40
30
20
10
0
Long interval 60min.
post-reperfusion
Long interval 60min.
post-reperfusion
Short interval Vehicle Short interval Vehicle
7-Day Follow-Up 45-Day Follow-Up
In
fa
rc
t S
iz
e 
(%
LV
)
100
80
60
40
20
0
In
fa
rc
t S
iz
e 
(%
AA
R)
60
40
20
0
LV
EF
 (%
)
Long interval 60min.
post-reperfusion
Long interval 60min.
post-reperfusion
Short interval Vehicle Short interval Vehicle
7-Day Follow-Up 45-Day Follow-Up
Long interval 60min.
post-reperfusion
Long interval 60min.
post-reperfusion
Short interval Vehicle Short interval Vehicle
7-Day Follow-Up 45-Day Follow-Up
A
B
C
MIS expressed as %LV (A), AAR (B), and LVEF (C) were assessed by CMR at 7 and 45 days
post-infarction in the 4 groups of the animal study. Dots indicate individual data; box and
whiskers indicate Tukey boxplots. *p < 0.05 compared with other groups. Abbreviations
as in Figure 2.
J A C C V O L . 6 7 , N O . 1 8 , 2 0 1 6 García-Ruiz et al.
M A Y 1 0 , 2 0 1 6 : 2 0 9 3 – 1 0 4 Metoprolol Timing in STEMI
2101oral metoprolol after reperfusion (8). The IV pre-
reperfusion metoprolol strategy was associated with
smaller infarcts (6), improved long-term LVEF, and
fewer cases of chronic severe LV dysfunction and
consequent ICD indications (7). The present study
added complementary information showing that a
longer period of onboard metoprolol before reperfu-
sion resulted in stronger cardioprotection. Infarcts
were signiﬁcantly smaller in the long- versus short-
interval patient group, and at 6-month follow-up,
only the long-interval group showed a signiﬁcantly
higher LVEF than the control group. Surprisingly,
these effects were observed even though total
ischemia duration (time from symptom onset to
reperfusion) was signiﬁcantly longer in the long-
interval group than in the short-interval group (214
min vs. 160 min; p < 0.001). Ischemia duration at the
time of bolus administration was similar in the long-
and short-interval groups (135 min vs. 130 min), so the
difference in total ischemia duration was due to
the difference in the bolus-to-reperfusion interval.
The likely explanation for this difference is that
patients in the short-interval group were diagnosed
either at the PPCI hospital or close to it, whereas
patients in the long-interval group were likely diag-
nosed far from the PPCI center.
The results thus indicated that early IV metoprolol
has a greater cardioprotective effect when followed by
a period of continued ischemia before reperfusion, a
ﬁnding with potentially important implications for
managing STEMI patients. For example, in regions
with longer transport times to the PCI center, early
metoprolol administration might counterbalance the
deleterious effect of longer ischemia duration. If so,
the cardioprotection afforded by postponing PPCI af-
ter early IV metoprolol might strengthen the recom-
mendation for PPCI over thrombolysis in patients who
receive this treatment. However, this hypothesis is
currently speculative, as no data are available on the
effect of metoprolol in patients undergoing throm-
bolysis. The main report on the METOCARD-CNIC trial
showed that patients in the IV metoprolol arm had
signiﬁcantly lower rates of VF (6), and the known ef-
fect of metoprolol on primary VF might additionally
beneﬁt patients with longer transits between diag-
nosis site and PPCI center. The sensitivity analysis
showed that after normalizing for total ischemia
duration, every 10 min of onboard metoprolol reduced
infarct size by 1.1 g (Table 3). Further analysis of the
METOCARD-CNIC cohort has indicated strong beneﬁts
of early IV metoprolol in the subpopulation of STEMI
patients treated in the out-of-hospital setting (19).
This phenomenon is being explored further in the
ongoing EARLY BAMI (Early Beta blocker
CENTRAL ILLUSTRATION Metoprolol Timing and Cardioprotection in STEMI
García-Ruiz, J.M. et al. J Am Coll Cardiol. 2016;67(18):2093–104.
The administration of intravenous (IV) metoprolol before reperfusion reduces infarct size in ST-segment elevation myocardial infarction (STEMI) patients undergoing
primary angioplasty. However, the cardioprotective effect of metoprolol varies depending on the timing of its administration during ongoing ischemia. The longer the
period of onboard metoprolol before reperfusion, the greater the reduction of infarct and the better the long-term left ventricular ejection fraction (LVEF). On the basis
of these data, the earlier metoprolol is administered after STEMI diagnosis, the higher the cardioprotection. Cath lab ¼ catheterization laboratory.
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2102Administration before reperfusion in patients with ST-
Elevation Myocardial Infarction) trial, a study of pa-
tients recruited in the out-of-hospital setting and
randomized to IV metoprolol or placebo (20), although
the timing and dose of metoprolol in this trial is
different from that in METOCARD-CNIC trial.
Using the same animal model, we previously
identiﬁed pre-reperfusion metoprolol as a strategy
able to reduce infarct size (6) and subsequently pro-
posed amelioration of reperfusion injury as the
mechanism underlying this effect (14). Preliminary
results, led by our group, showed that IV adminis-
tration of metoprolol exerts cardioprotection against
acute MI by inhibiting acute deleterious neutrophil-
platelet interactions at reperfusion (21), but a poten-
tial effect by decreasing ischemic injury cannot be
ruled out. The greater cardioprotective effect with
earlier administration of IV metoprolol could corre-
spond to 2 mechanisms: 1) IV metoprolol reduces
ischemia-related damage (slows the rate of myocar-
dial death during ischemia) by reducing myocardial
oxygen consumption; or 2) to reduce reperfusion-
related injury, metoprolol needs to be “onboard” (in
the systemic circulation) for some time. We speculate
that both mechanisms are implicated in the infarct-
limiting effect of metoprolol. This dual effect on
ischemia- and reperfusion-related injuries identiﬁedmetoprolol as a unique agent for reducing ischemia/
reperfusion injury; however, the precise mechanism
underlying this phenomenon falls beyond the scope
of this study.
Infarct size is a major predictor of post-STEMI
mortality and morbidity, and there is a need for
adjunct therapies that reduce the extent of myocardial
damage associated with reperfusion (3). Early admin-
istration of 15 mg IV metoprolol is 1 of the few in-
terventions that has been shown to reduce MIS and
improve long-term LVEF (6,7): MIS and LVEF are well-
validated surrogates of mortality. The ongoing EARLY
BAMI trial (20) will determine whether the infarct-
limiting effects of early IV metoprolol are consistent
in a less restricted STEMI population; unlike
METOCARD-CNIC, EARLY BAMI includes patients
presenting up to 12 h after symptom onset and evalu-
ates infarctions in the anterior and other locations.
Conversely, the dose and the timing of metoprolol
administration in EARLY BAMI and METOCARD-CNIC
are dissimilar. However, a large clinical trial powered
to detect differences in hard endpoints is still needed.
STUDY LIMITATIONS. Post hoc analysis of clinical
trials has certain inherent limitations, 1 being the
possibility of residual confounders that could affect
the results. For this reason, we tested the hypothesis
generated in the post hoc analysis in a well-validated
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: IV administration of metoprolol before primary
angioplasty reduces infarct size in patients with STEMI, and
earlier administration is associated with smaller infarct size
and higher residual LVEF.
TRANSLATIONAL OUTLOOK 1: Systems should be developed
to facilitate earlier IV administration of metoprolol for patients
developing STEMI in regions where the time to primary PCI is
lengthy.
TRANSLATIONAL OUTLOOK 2: In STEMI patients with no
contraindications (i.e., Killip class I to II, no hypotension or
atrioventricular block), IV metoprolol (15 mg) should be
considered immediately after STEMI diagnosis without delay.
TRANSLATIONAL OUTLOOK 3: Current clinical guidelines
recommend IV injection of metoprolol in STEMI patients with
ongoing ischemia and no contraindications (Class IIa). Not
adhering to this recommendation might result in larger
infarctions associated with poor long-term prognosis.
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2103experimental model of STEMI (pig ischemia/
reperfusion). We used the same imaging technology
(CMR) as the clinical trial and similar short- and
long-term follow-up time points. This controlled
setting generated similar results to the clinical trial:
pigs receiving metoprolol long before reperfusion had
signiﬁcantly smaller infarcts and higher long-term
ventricular function. This dual clinical-experimental
approach added robustness to the results observed.
However, animal models present some limitations.
First, myocardial collateral ﬂow may play a role in the
ﬁnal infarct size. Pigs are widely used in this regard
because their cardiac size, hemodynamics, and coro-
nary anatomy closely resemble that of humans and
also because they have negligible collateral ﬂow, thus
reducing this potential bias. Second, experimental
protocols (anesthetics, pig strain, adjuvant drugs, and
so on) vary across laboratories, and these factors
might affect infarct-size progression (22,23). Howev-
er, although this might inﬂuence the differences of
our results to that of other laboratories (something
obvious for infarct size in control subjects), it should
not affect the current results because all experimental
groups underwent the same protocol; therefore, the
treatment effect of metoprolol is real.
CONCLUSIONS
This study showed that in STEMI patients scheduled
for PPCI, the longer the interval between IV meto-
prolol bolus and reperfusion, the higher the car-
dioprotection afforded by metoprolol, resulting in
smaller infarct size and higher LVEF. These clinical
results were validated in a pig study, in which
metoprolol administration long before reperfusion
was associated with smaller infarcts and better long-
term LVEF. Given that reperfusion should not be
delayed under any circumstance, the best strategy for
attaining cardioprotection with metoprolol is to inject
an IV bolus (15 mg according to the METOCARD-CNIC
trial) immediately after STEMI diagnosis in patients
with no contraindications.
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